NXL — Nexalin Technology, Inc.

Nasdaq · Health Care · Health Care Equipment & Supplies · CIK 1527352 ·
Last close
$0.46
Market Cap
$9.92M
52W High
$0.64
52W Low
$0.31
ADV30
277,514
Next earnings
Nexalin Technology, Inc., a medical device company, designs and develops neurostimulation products for the treatment of mental health epidemic in the United States and China. The company offers Generation 1, an easy-to-administer medical device which utilizes bioelectronic medical technology to treat anxiety, insomnia, and depression without the need for drugs or psychotherapy; and Generation 2 and Generation 3 headset devices for the treatment of depression, substance use disorder, traumatic brain injury, post-traumatic stress disorder, opioid addiction, alcoholism, and chronic pain, as well as alzheimer's disease, and dementia. Nexalin Technology, Inc. is headquartered in Houston, Texas.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGrossProfit OpIncomeNetIncomeAssets CashLiabilities
Mar 2026 14,950 13,133 -2,119,902 -2,096,837 3,694,633 1,207,895 808,364
Dec 2025 171,895 150,866 -2,413,167 -2,376,546 4,635,319 654,783 887,333
Sep 2025 18,149 14,201 -2,345,631 -2,276,311 5,125,940 590,075 357,524
Jun 2025 70,588 47,750 -1,620,858 -1,580,987 6,563,982 431,320 600,584

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-4,957,658
Investing CF
$-131,991
Financing CF
$5,039,734
CapEx
$-96,859
Dividends Paid
Buybacks
EPS Diluted TTM
$-0.61
As of
2026-05-10

Balance + Analyst (yfinance extras)

Retained Earnings
$-92,867,412
Inventory
$131,473
Receivables
$81,571
ST Investments
$3,068,429
EBIT TTM
$-8,390,881
Pretax Income TTM
$-8,221,133
Interest Exp TTM
Analysts
1

Yahoo Snapshot (yfinance, live)

Total Revenue
$275,582
EBITDA
$-8,471,964
Free Cash Flow
$-2,250,682
Enterprise Value
$6,594,419
Total Cash
$2,708,485
Total Debt
$0
Shares Out
21,540,662
Trailing EPS
$-0.46
Book Value
$0.14
ROE
-319.7%
ROA
-161.1%
Div Yield

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOpIncome NetIncomeAssetsLiabilities EquityOCF
Dec 2025 301,647 -8,390,881 -8,222,181 4,635,319 887,333 -4,957,658
Dec 2024 168,721 -7,754,646 -7,607,182 4,222,732 546,694 -3,944,390
Dec 2023 110,748 -5,696,296 -4,648,709 3,631,916 425,281 -3,835,384
Dec 2022 1,321,357 -1,833,031 -1,697,816 7,432,136 1,953,449 -2,215,699

TTM Snapshot

Revenues TTM
NetIncome TTM
OpCashFlow TTM
Assets (Latest)
Forward EPS
$-0.31

Peers — same industry

TickerNameMarket CapLastDaily %
CODX Co-Diagnostics, Inc. $9.55M $2.61
MBAI Check-Cap Ltd $9.43M $1.22
HSCS HeartSciences Inc. $9.02M $2.74
SINT Sintx Technologies, Inc. $10.94M $1.72
OSRH OSR Health, Inc. $11.53M $0.33

News headlines (Yahoo Finance, 1h cache)

Nexalin Technology Announces that the Investigator of Its Brazilian Clinical Trial Received the Young Researcher Award at BRAIN 2026 for Research Evaluating the Company’s Proprietary DIFS™ Platform
2026-06-23 12:30 · Yahoo
Nexalin Technology Announces Two Clinical Abstracts Accepted for Presentation at the 2026 NYC Neuromodulation Conference Highlighting Preliminary Clinical Results Across Anxiety, Depression, Insomnia
2026-06-16 13:15 · Yahoo
Nexalin Technology Reports Compelling Clinical Trial Results in Brazil to Support Product Launch. Trial Demonstrates 77.8% Anxiety Response Rate and Durable Benefits Across Depression, Insomnia and Qu
2026-06-10 13:15 · Yahoo
EXCLUSIVE: Nexalin Brazil Trial Shows Benefits Across Anxiety, Sleep And Quality Of Life
2026-06-10 13:01 · Yahoo
Nexalin Technology Announces Issuance of U.S. Patent Covering Dynamic Frequency Stimulation for Anxiety, Depression and Insomnia
2026-06-04 14:00 · Yahoo
Nexalin Technology Secures Key Neurostimulation Legislative Provision & Commends U.S. House-Passed Report Language Expanding Non-Invasive Deep Brain Neurostimulation Research at the Department of Vete
2026-05-21 12:30 · Yahoo
Nexalin Acquires AI-Integrated Digital Health Platform Behind HALO™ Clarity and Nexalin NeuroCare™ Ahead of Planned FDA Pivotal Trial
2026-05-19 12:30 · Yahoo
Nexalin Announces Peer-Reviewed Publication with Neuroimaging Data in Psychotherapy and Psychosomatics Highlighting Brain-Network Effects and Clinical Improvement in Chronic Insomnia
2026-04-28 13:15 · Yahoo
Nexalin Technology Advances Pivotal Clinical Trial of HALO™ Clarity Toward Q2 2026 Enrollment
2026-04-22 13:35 · Yahoo
RedChip's Biotech Investor Conference Replays Now Available
2026-04-20 12:00 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.